Translational andrology and urology最新文献

{"title":"Current status of non-surgical treatments for Peyronie's disease.","authors":"Sung Chul Kam, Yu Seob Shin, Ho Seok Chung","doi":"10.21037/tau-2025-732","DOIUrl":"https://doi.org/10.21037/tau-2025-732","url":null,"abstract":"","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"15 3","pages":"72"},"PeriodicalIF":1.7,"publicationDate":"2026-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13062826/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147676614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construction of a survival model for predicting biochemical recurrence of prostate cancer based on propionate metabolism-related genes.","authors":"Baosai Lu, Yalin Niu, Xi Liu, Chenming Zhao, Yuewei Yin","doi":"10.21037/tau-2025-aw-811","DOIUrl":"https://doi.org/10.21037/tau-2025-aw-811","url":null,"abstract":"<p><strong>Background: </strong>About 20-40% of prostate cancer (PCa) develop biochemical recurrence (BCR) after surgery, and propionate metabolism may contribute to tumor progression. BCR remains a major clinical challenge in PCa, as current tools based on histopathology and prostate-specific antigen (PSA) fail to capture the molecular heterogeneity driving the disease. While metabolic reprogramming is known to facilitate post-treatment adaptation, the specific role of propionate metabolism in this context remains largely unexplored. Therefore, this study aimed to systematically investigate propionate metabolism-related genes (PMRGs) to develop a novel prognostic model for the improved early prediction of recurrence.</p><p><strong>Methods: </strong>In this study, The Cancer Genome Atlas-Prostate Adenocarcinoma (TCGA-PRAD), GSE70770 and 412 PMRGs were employed. Differentially expressed genes (DEGs) in PCa and control and DEGs2 in BCR and no BCR samples obtained by differential analysis were intersected with PMRGs to get candidate genes. After Cox and least absolute shrinkage and selection operator (LASSO) regression analyses, biomarkers were identified to construct risk models.</p><p><strong>Results: </strong>Biomarkers including <i>BMP6</i>, <i>NAT2</i>, <i>PTGS2</i>, <i>LPL</i> were identified to construct risk model after a series of analyses. Meanwhile, the nomogram for risk score can effectively predict BCR-free recurrence in PCa patients. Besides, 16 signaling pathways were significantly associated with riskScore, such as cell cycle and DNA replication. In immune-related analysis, six immune cells were significantly associated with the biomarkers. Furthermore, Wee1 Inhibitor_1046, Paclitaxel_1080, etc. were therapeutic drugs for PCa patients. Finally, the expression trend of four biomarkers was confirmed in clinical samples.</p><p><strong>Conclusions: </strong>In this study, PMRGs were regarded as biomarkers in PCa for risk model construction, which suggest that propionate metabolism represents a biologically relevant axis in PCa recurrence and may offer a novel framework for biomarker-driven risk assessment.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"15 3","pages":"79"},"PeriodicalIF":1.7,"publicationDate":"2026-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13062814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147676430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of RNA processing-related gene-based bladder cancer subtypes for prognosis and immune landscape assessment.","authors":"Quanqi Liu, Pengfei Zhou, Daxue Tian","doi":"10.21037/tau-2025-aw-780","DOIUrl":"https://doi.org/10.21037/tau-2025-aw-780","url":null,"abstract":"<p><strong>Background: </strong>Bladder cancer (BLCA) is a clinically complex malignancy characterized by high heterogeneity and recurrence, posing significant challenges for patient management. Growing evidence implicates dysregulated RNA processing, a crucial layer of gene expression control, as a key driver of BLCA pathogenesis and progression, highlighting its potential as a therapeutic vulnerability. This study aims to identify novel molecular subtypes based on RNA processing-related genes (RPRGs) and construct a robust prognostic risk model to improve survival prediction and personalize treatment strategies, particularly in the context of the immune landscape and immunotherapy response.</p><p><strong>Methods: </strong>We analyzed BLCA data from The Cancer Genome Atlas (TCGA) (training cohort, N=394) and Gene Expression Omnibus (GEO) (validation cohort, GSE32894, N=224). Using RPRGs from the Molecular Signatures Database (MSigDB), we identified prognostic genes via univariate Cox regression and performed molecular subtyping with the non-negative matrix factorization (NMF) algorithm. A prognostic model was constructed using least absolute shrinkage and selection operator (LASSO) Cox regression (\"glmnet\" package), and its performance was validated using receiver operating characteristic (ROC) analysis (timeROC). Immune infiltration was assessed via single-sample gene set enrichment analysis (ssGSEA), ESTIMATE, and CIBERSORT, while functional enrichment was analyzed using GSEA and clusterProfiler. Drug sensitivity was predicted using the CellMiner and DGIdb databases, along with the \"pRRophetic\" package.</p><p><strong>Results: </strong>Using RPRGs, we stratified BLCA into two molecular subtypes and developed an 8-gene prognostic model via LASSO Cox regression. The model effectively stratified patients into high-risk (poor prognosis) and low-risk (favorable prognosis) groups in both TCGA and GEO cohorts [area under the curve (AUC) >0.71]. High-risk group displayed immunosuppressive traits [e.g., elevated Tumor Immune Dysfunction and Exclusion (TIDE) score, M2 macrophage enrichment] and reduced immunotherapy response, while low-risk group showed elevated tumor mutation burden (TMB) and CD8⁺ T cell infiltration. Functional enrichment revealed extracellular matrix pathways in high-risk cases, and drug sensitivity profiling identified signature gene-chemotherapy associations.</p><p><strong>Conclusions: </strong>Based on RPRGs, this study establishes a novel risk model that effectively stratifies BLCA patients, not only predicting prognosis but also revealing its close association with the tumor microenvironment and immunotherapy response, providing a new tool for personalized treatment.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"15 3","pages":"74"},"PeriodicalIF":1.7,"publicationDate":"2026-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13062870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147676733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiomics and deep learning fusion model based on multiphasic CT for predicting HER2 expression status in bladder urothelial carcinoma: a multicenter study.","authors":"Wenbang Pan, Liu Yang, Lin Yang, Chaohui Gu, Qiang Lv, Yingyi Zhang, Mingyue Li","doi":"10.21037/tau-2025-1-899","DOIUrl":"https://doi.org/10.21037/tau-2025-1-899","url":null,"abstract":"<p><strong>Background: </strong>Human epidermal growth factor receptor 2 (HER2) overexpression is a key therapeutic target for novel antibody-drug conjugates (ADCs) like disitamab vedotin (RC48) in bladder urothelial carcinoma (BLCA), but immunohistochemistry-based assessment is limited by intratumoral heterogeneity and sampling bias. A noninvasive and reliable imaging-based approach is therefore urgently needed. Therefore, this study aimed to construct a noninvasive, imaging-based multimodal model for predicting HER2 expression status in BLCA using tri-phasic CT.</p><p><strong>Methods: </strong>A total of 411 patients from three institutions (2021-2024) who underwent tri-phasic contrast-enhanced computed tomography (CT) and HER2 immunohistochemistry (IHC) were included. Patients were classified as HER2-positive (IHC 2+/3+) or negative (IHC 0/1+) based on therapeutic criteria for ADCs. Patients were divided into training, internal validation, and external validation cohorts. Radiomics models, 2.5D and 3D ResNet50 deep learning models, a clinical model, and a multimodal fusion model were developed. Model performance was evaluated using receiver operating characteristic (ROC) analysis, calibration curves, and decision curve analysis.</p><p><strong>Results: </strong>Tumor architecture (sessile pattern), hydronephrosis, pelvic pain, and radiological lymph node status were identified as independent predictors of HER2 positivity. The 2.5D ResNet50 model achieved an external area under the curve (AUC) of 0.827, significantly outperforming the 3D model (AUC =0.608). The multimodal fusion model showed the best performance, with AUCs of 0.960, 0.908, and 0.873 in the training, internal validation, and external validation cohorts, respectively. In the external cohort, accuracy, sensitivity, and specificity were 0.819, 0.857, and 0.784. The multimodal model significantly outperformed all single-modality models.</p><p><strong>Conclusions: </strong>A tri-phasic CT-based multimodal model enables noninvasive assessment of HER2 expression status in BLCA, providing a promising tool for selection of patients likely to benefit from ADC therapy.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"15 3","pages":"83"},"PeriodicalIF":1.7,"publicationDate":"2026-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13062831/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147676898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Astaxanthin provides antioxidant protection in rats with chronic nonbacterial prostatitis by regulating the MAPK signaling pathway.","authors":"Jiahao Jiang, Huajie Song, Jing Chen, Yan Zeng, Hengcheng Zhu, Mao Ding, Lingqi Liu","doi":"10.21037/tau-2025-743","DOIUrl":"https://doi.org/10.21037/tau-2025-743","url":null,"abstract":"<p><strong>Background: </strong>Chronic nonbacterial prostatitis (CNP) is the most common type of symptomatic prostatitis that afflicts men due to various discomforts. Owing to its anti-inflammatory and antioxidant properties, astaxanthin (AST) can be used in the treatment of various chronic inflammatory diseases. This study was conducted to assess the effects of AST and investigate the underlying mechanisms in a rat model of CNP.</p><p><strong>Methods: </strong>A rat model of CNP was established by intraprostatic carrageenan (0.1 mL 1% λ-carrageenan saline solution) injection. AST (40 and 80 mg/kg/day) was administered orally for 4 weeks, and blood and prostate tissue samples were collected for examination.</p><p><strong>Results: </strong>The prostate weight and index were lower in AST-treated rats than in rats with CNP. In prostate tissue and serum, AST increased superoxide dismutase and glutathione peroxidase activity. Meanwhile, AST reduced inflammatory factors [tumor necrosis factor-α, interleukin (IL)-1β, and IL-6] expression in prostate tissue and serum. Besides, AST also reduced nerve growth factor expression in prostate tissue. Furthermore, AST inhibited mitogen-activated protein kinase (MAPK) pathway activation.</p><p><strong>Conclusions: </strong>This study showed that AST exerts antioxidant and protective effects against CNP, mediated through MAPK signaling suppression. The study results provide evidence supporting the potential use of AST in the treatment of CNP.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"15 3","pages":"73"},"PeriodicalIF":1.7,"publicationDate":"2026-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13062874/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147677015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From symptomatic relief to restorative medicine: a comprehensive review of diabetic erectile dysfunction.","authors":"Huan Wang, Chuangui Li, Tianzi Zhang, Siqi Li","doi":"10.21037/tau-2025-1-945","DOIUrl":"https://doi.org/10.21037/tau-2025-1-945","url":null,"abstract":"<p><p>Diabetic erectile dysfunction (DMED) represents one of the most prevalent and debilitating complications in men with diabetes, characterized by a complex multifactorial pathogenesis and often suboptimal response to conventional therapies. This review comprehensively summarizes the current understanding of DMED mechanisms and evaluates the evolving therapeutic landscape. We highlight oxidative stress as a pivotal central hub triggered by hyperglycemia, which orchestrates a cascade of detrimental events. Beyond classical endothelial dysfunction and RhoA/ROCK pathway activation, we discuss emerging pathogenic targets, including the activation of the NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome leading to pyroptosis, ferroptosis-induced smooth muscle loss, and epigenetic dysregulation (e.g., upregulated miR-155). Furthermore, the \"gut-penis axis\" is explored as a novel link between microbiota dysbiosis and systemic inflammation affecting erectile function. Critically, this review assesses the paradigm shift from symptomatic management to restorative therapies. While phosphodiesterase type 5 inhibitors (PDE5i) remain the first-line treatment, they exhibit a non-response rate of approximately 40-50% in diabetic men due to severe neuropathy and endothelial damage. Consequently, emerging regenerative modalities are gaining prominence. We evaluate the efficacy of low-intensity extracorporeal shockwave therapy (Li-ESWT) in promoting angiogenesis and the strategic transition from stem cell transplantation to cell-free exosome therapies to overcome immunogenicity. Additionally, novel pharmacotherapies such as sodium-glucose cotransporter-2 (SGLT2) inhibitors are discussed for their potential to reduce sympathetic overactivation. Finally, we propose a comprehensive, stepwise clinical management algorithm-ranging from metabolic optimization to regenerative interventions and penile prostheses-to achieve personalized precision medicine for refractory DMED patients.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"15 3","pages":"88"},"PeriodicalIF":1.7,"publicationDate":"2026-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13062855/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147676564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global research landscape and technological breakthroughs in post-prostatectomy urinary incontinence management: a bibliometric review and visualized study.","authors":"Xu Zhang, Ju Zhang, Tong Fu, Jianfeng Shao, Yuqing Chen, Xuchu Duan","doi":"10.21037/tau-2025-1-908","DOIUrl":"https://doi.org/10.21037/tau-2025-1-908","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer (PCa) is the second leading cause of cancer-related deaths in men worldwide. Treatment frequently leads to urinary incontinence (UI), yet no global standard exists, revealing regional disparities. This paper states current research and innovations in managing this complication, offering guidance to improve treatment outcomes and enhance patients' quality of life (QoL).</p><p><strong>Methods: </strong>This study analyzed 2,642 peer-reviewed articles on PCa and UI (January 1991 to November 11, 2024) from the Web of Science Core Collection (WoSCC). Using VOSviewer, Citespace, Excel, R4.4.1, and Pajek, it examined publication trends, country/institution distributions, journal outputs, authorship patterns, and citation networks. Findings highlighted research hotspots, aided by standardized VOSviewer-based preprocessing.</p><p><strong>Results: </strong>The USA and Germany lead research on PCa and UI, with Memorial Sloan-Kettering Cancer Center publishing the most articles and Harvard University being the most cited institution. Martin G. Sanda is the author with the most publications, and the <i>Journal of Urology</i> has the most publications. Robot-assisted radical prostatectomy (RP) is a key emerging technique, while stress UI remains a prevalent post-surgery issue. A bibliometric analysis using the WoSCC data reveals global trends, highlighting shifts from traditional surgery to robotic methods and an increasing focus on quality-of-life outcomes.</p><p><strong>Conclusions: </strong>Recent advances in UI management after PCa, especially RP, have markedly improved patient outcomes. Revised American Urological Association guidelines address these complications and recommend interventions like artificial urinary sphincters, reflecting a global commitment to enhance QoL.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"15 3","pages":"81"},"PeriodicalIF":1.7,"publicationDate":"2026-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13062816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147676571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urethral leiomyoma mimicking urethral diverticulum: a rare case report and brief literature review.","authors":"Tae Woong Han, Ki Hong Kim, Ji Hye Lee, Si Hyun Kim","doi":"10.21037/tau-2026-1-0013","DOIUrl":"https://doi.org/10.21037/tau-2026-1-0013","url":null,"abstract":"<p><strong>Background: </strong>Urethral leiomyoma is an uncommon benign smooth-muscle tumor that typically affects women of reproductive age and presents with lower urinary tract symptoms or a periurethral mass. Preoperative misclassification as urethral diverticulum or Skene's gland disease is frequent because clinical and imaging features overlap. Although magnetic resonance imaging (MRI) can suggest a solid periurethral mass and delineate its relation to the urethral lumen and sphincter, definitive diagnosis requires surgical excision with histopathologic confirmation. This case is noteworthy because a mid-urethral leiomyoma closely simulated a diverticulum on initial clinical assessment, and the final diagnosis hinged on targeted MRI review and <i>en bloc</i> vaginal excision with preservation of urethral integrity.</p><p><strong>Case description: </strong>A 44-year-old woman presented with urethral pain and dysuria. Initial working diagnosis was urethral diverticulum. Pelvic MRI (dynamic, multiparametric) revealed a well-circumscribed 3-cm solid periurethral mass centered at the mid urethra without a demonstrable neck to the urethral lumen. The patient underwent vaginal <i>en bloc</i> excision via an inverted U-shaped incision under general anesthesia; the urethra was dissected free without injury. Gross specimen measured 3.8 cm × 3.0 cm. Histology showed intersecting bundles of bland spindle cells consistent with leiomyoma; immunohistochemistry (IHC) was desmin and smooth muscle actin (SMA) positive and S-100/CD34 negative, with Ki-67 ≈1%. Recovery was uneventful with acetaminophen-only analgesia; Foley catheter was removed after 1 day, and she was discharged on postoperative day 1. At 3 months, there were no complications and dysuria had resolved.</p><p><strong>Conclusions: </strong>Mid-urethral leiomyoma can mimic urethral diverticulum. Careful MRI review for a solid lesion without luminal communication, followed by complete local excision that preserves urethral integrity, leads to accurate diagnosis and excellent short-term outcomes. This report provides practical imaging and operative cues for periurethral smooth-muscle tumors.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"15 3","pages":"92"},"PeriodicalIF":1.7,"publicationDate":"2026-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13062812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147676996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined anatomical parameters predict benign prostatic hyperplasia-related lower urinary tract symptom severity: a volume-stratified study.","authors":"Yao-Xia Wang, Yu-Hua Huang, Yi Li, Yin-Ying Liang, Ling-Yan Zhang, Yu-Min Zhuo, Zheng Chen, Jun Huang","doi":"10.21037/tau-2025-1-919","DOIUrl":"https://doi.org/10.21037/tau-2025-1-919","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;The association between prostate volume (PV) and lower urinary tract symptoms (LUTS) in benign prostatic hyperplasia (BPH) is inconsistent, as significant symptoms frequently occur even with small prostates. Although ultrasonography noninvasively ascertains anatomical parameters, such as intravesical prostatic protrusion (IPP) and bladder neck angle (BNA), their predictive value across different prostate sizes remains unclear. We aimed to examine the association between prostatic anatomical parameters and the severity of LUTS in patients with BPH across different PV categories, and to develop a predictive model for voiding dysfunction based on these anatomical parameters.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This retrospective study included 257 patients with BPH who visited The First Affiliated Hospital of Jinan University for LUTS between January 2023 and March 2024. Transrectal ultrasound was used to measure the PV, IPP, BNA, prostatic urethral angle (PUA), prostatic urethral length (PUL) and other anatomical parameters. Patients were stratified by PV (&lt;30 &lt;i&gt;vs.&lt;/i&gt; ≥30 mL). The International Prostate Symptom Score (IPSS) and maximum urinary flow rate (Qmax) were recorded. Prostatic anatomical parameters were correlated with the LUTS severity using Spearman's rank correlation analysis, followed by linear regression modeling to quantify these associations. Predictive models were constructed based on the parameters identified by logistic regression. Receiver operating characteristic (ROC) curves were utilized to determine optimal cutoff values and evaluate model performance.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Of 257 patients with BPH, 91 (35.4%) and 166 (64.6%) belonged to the large-volume and small-volume groups, respectively. Multivariable linear regression revealed that, in small prostates, PUL (β=0.20), BNA (β=0.12) and age (β=0.11) independently predicted the International Prostate Symptom Score total score (IPSS-t), whereas PUL (β=-0.29) and BNA (β=-0.09) predicted Qmax. For large prostates, IPP (β=0.29), age (β=0.14), BNA (β=0.09), and PUA (β=0.08) predicted IPSS-t, whereas IPP (β=-0.21) and PUA (β=-0.09) predicted Qmax. Logistic regression demonstrated that the combination of IPP, BNA, and PUA constituted a significant predictor of voiding dysfunction (Qmax &lt;10 mL/s) in patients with large PV. In the large-volume group, the combined model achieved an area under the curve (AUC) of 0.94 [95% confidence interval (CI): 0.90-0.99], which indicated robust discriminative power.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Volume-stratified analysis provides a more precise assessment of prostate anatomical parameters in BPH. A model integrating IPP, BNA, and PUA demonstrates favorable accuracy in predicting voiding dysfunction specifically in large‑volume BPH. These findings underscore the clinical utility of ultrasonographic anatomical assessment and support volume‑stratified management. Prospective multicenter validation is req","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"15 3","pages":"75"},"PeriodicalIF":1.7,"publicationDate":"2026-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13062856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147677018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comorbidity alterations between time for diagnosis and radical cystectomy in patients with muscle invasive bladder cancer undergoing neoadjuvant chemotherapy.","authors":"Elvira Oskarsson, Markus Johansson, Oskar Lidén, Farhood Alamdari, Johan Svensson, Amir Sherif","doi":"10.21037/tau-2025-192","DOIUrl":"https://doi.org/10.21037/tau-2025-192","url":null,"abstract":"<p><strong>Background: </strong>Comorbidity alterations during neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer (MIBC) are not well studied. Comorbidity-estimates are mainly based on calculations at diagnosis. It is unknown if comorbidities alter in this patient group. This study aimed to investigate if comorbidity alterations during treatment need to be considered, for scientific evaluations.</p><p><strong>Methods: </strong>A retrospective study of comorbidity alterations on MIBC patients undergoing NAC using age adjusted Charlson Comorbidity Index (CACI). We identified 684 patients between 2007-2022 from four Swedish cystectomy centers, a total of 320 were enrolled in the study. Inclusion criteria were nondisseminated MIBC, cT2-4aN0M0, NAC-treatment or NAC-eligibility. Medical files were reviewed and CACI were assessed and graded at three checkpoints during treatment: At diagnosis, post-NAC and pre-surgery. The cohort was divided into three subgroups, NAC complete, NAC incomplete and NAC-eligible. Data was retrospectively analyzed in SPSS Statistics 29.0 using descriptive statistics, one-way analysis of variance (ANOVA) and t-test.</p><p><strong>Results: </strong>The total cohort (n=320) had an increase in CACI, 0.11 CACI points, between diagnosis and prior to surgery [95% confidence interval (CI): 0.06-0.15, P<0.001]. The NAC-incomplete group had the highest increase in CACI, 0.21 CACI points from diagnosis to pre-surgery (95% CI: 0.03-0.39, P=0.01). The NAC-complete group also had an increase in CACI, 0.11 CACI points from diagnosis to pre-surgery (95% CI: 0.06-0.15, P<0.001). The NAC-eligible group had no significant CACI-alterations. The most common events causing an increase in CACI was suspected peptic ulcer (85.2%).</p><p><strong>Conclusions: </strong>There is a statistically significant increase of comorbidity in the total cohort as well as for two of the three subgroups, the NAC complete group and the NAC incomplete group. However, the increases are subtle and of limited clinical significance. This suggests that regardless of adverse events, complications, or progression, comorbidities only slightly change over time in the patient group. All together, answering the primary question if a comorbidity measurement at any moment on the timeline is sufficient.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"15 3","pages":"77"},"PeriodicalIF":1.7,"publicationDate":"2026-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13062850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147676970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}